For many individuals of African ancestry, a specific genetic blueprint can signal a heightened risk of kidney failure. The APOL1 gene, when carrying high-risk variants, has long been recognized as a primary driver of chronic kidney disease (CKD). However, genetics alone rarely notify the whole story; many people with these high-risk genotypes never develop kidney disease, while others progress rapidly toward end-stage renal failure.
The missing piece of the puzzle has been a way to identify exactly who is at the highest risk of progression and when that decline will commence. A new approach using a proteomic risk score for early prediction of kidney disease progression aims to bridge this gap, moving beyond static genetic markers to a dynamic “snapshot” of the proteins circulating in the blood.
By analyzing thousands of proteins in the plasma of high-risk individuals, researchers have developed a tool—the APOL1 Proteomic Risk Score (APRS)—that can predict kidney events and mortality with significantly higher precision than traditional clinical markers alone. This shift toward precision medicine could allow doctors to intervene years before a patient requires dialysis or a transplant.
Beyond Genetics: The Role of Plasma Proteins
While the presence of APOL1 risk alleles (specifically the G1 and G2 variants) provides a baseline of risk, it does not explain the variability in how the disease manifests. Proteins, the workhorses of the cell, reflect the real-time state of an organ’s health. When the kidneys begin to struggle, the composition of proteins in the blood shifts, creating a molecular signature of distress.
To capture this signature, researchers utilized the SomaScan platform, a high-throughput technology that uses modified DNA aptamers to probe the human proteome. This allowed the team to monitor 6,386 distinct proteins in the plasma of participants, searching for those most closely linked to the decline of kidney function.
The resulting APRS is not based on a single “magic bullet” biomarker. Instead, it is a weighted composite of nine specific proteins, combined with traditional clinical data. The proteins identified as key predictors include SPON1, SUMO2, EPHA10, REG3A, WFDC2, LYZ, MMP7, NPPB, and CILP2. When these are analyzed alongside age, sex, baseline estimated glomerular filtration rate (eGFR), and the urine albumin-to-creatinine ratio (UACR), the model provides a comprehensive risk profile.
The Blueprint of the Risk Score
The complexity of the APRS lies in its ability to balance multiple biological signals. Some proteins in the score may indicate inflammation, while others signal structural damage to the kidney’s filtering units. By integrating these signals, the score can identify patients who are “fast progressors” even if their current kidney function appears stable.
| Category | Key Predictors Included |
|---|---|
| Proteomic Markers | SPON1, SUMO2, EPHA10, REG3A, WFDC2, LYZ, MMP7, NPPB, CILP2 |
| Clinical Metrics | eGFR (Kidney function), UACR (Proteinuria) |
| Demographics | Age, Sex |
Rigorous Validation Across Global Cohorts
To ensure the score was not a fluke of one specific group, the researchers validated the APRS across three massive, diverse datasets. The primary development took place within the Penn Medicine BioBank (PMBB), a large academic repository that has enrolled over University of Pennsylvania Health System participants, with roughly 30% from non-European ancestries.
The model was then tested against the UK Biobank (UKBB), where researchers identified 1,171 individuals of African descent, and the Atherosclerosis Risk in Communities (ARIC) study, which included 314 African American participants. This cross-cohort validation is critical given that it proves the proteomic signature remains consistent regardless of the geographic location or the specific healthcare system of the patient.
The primary outcomes tracked were a composite of “kidney events”—which include the start of long-term dialysis, a diagnosis of end-stage kidney disease (ESKD), the need for a kidney transplant, or a decline in eGFR of 40% or more—as well as all-cause mortality. By including mortality in the composite, the researchers acknowledged that for many high-risk patients, cardiovascular events are a competing risk that occurs alongside kidney failure.
What This Means for Patient Care
For the average patient, the difference between a genetic test and a proteomic score is the difference between knowing you have a “predisposition” and knowing you are “currently progressing.”
Currently, many high-risk APOL1 carriers are monitored with standard blood and urine tests. However, these tests often only show significant changes after substantial kidney damage has already occurred. The APRS offers a window of opportunity for earlier intervention. If a patient is identified as high-risk via the proteomic score, clinicians can potentially implement more aggressive blood pressure control, optimize medications, or enroll the patient in clinical trials for targeted therapies earlier in the disease course.
This is particularly vital given the disparities in kidney health outcomes. People of African descent are disproportionately affected by CKD and face higher rates of ESKD. Tools like the APRS represent a move toward precision medicine, where treatment is tailored to the individual’s molecular profile rather than a one-size-fits-all approach based on population averages.
The Path to Clinical Implementation
While the results are promising, the transition from a research biobank to a local clinic requires further steps. The next phase of development will likely involve prospective trials to determine if using the APRS to guide treatment actually improves patient outcomes compared to standard care.
the cost and accessibility of proteomic profiling must be addressed. While the SomaScan platform is powerful, it is currently more expensive and less common than a standard creatinine test. The goal for researchers is to refine these markers into a more streamlined, cost-effective assay that can be deployed in community health centers, not just academic medical centers.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Please consult a healthcare provider for diagnosis and treatment of kidney disease.
The next confirmed milestone for this research will be the integration of these proteomic findings into ongoing clinical trials for APOL1-targeted therapies, which will test whether the score can accurately identify the patients who benefit most from new medications.
Do you have questions about genetic risk and kidney health? Share your thoughts or experiences in the comments below.
